India Pharmaceuticals Industry Strategic Research Report

The India Pharmaceuticals Market (IPM) is estimated at USD 27.8 billion in 2025 (base year), forecast to reach USD 50.0 billion by 2031, at a CAGR of approximately 8.4% across the 2025-2031 forecast period. Real historical data spans 2022-2024 (USD 20.8 billion in 2022), anchored to IQVIA India MIDAS and AIOCD-AWACS retail audit data, not estimated backward from a single base year.

This report independently verifies all 17 profiled companies' financial figures directly against their own official investor relations disclosures and annual reports, following a rigorous data refresh completed in August 2026 that identified and corrected several real discrepancies between commonly-cited estimates and companies' actual reported results, including Sun Pharmaceutical, Zydus Lifesciences, and Natco Pharma's FY2026 figures.

The GLP-1 sub-segment within Anti-Diabetic therapy is the fastest-growing category in the entire IPM at approximately 37.7% CAGR (IPM-tracked channel), and this report provides full reconciliation between India-specific IPM-tracked GLP-1 revenue and the broader Global GLP-1 Drug Market report's India country-line figures.

This report profiles 17 companies including Sun Pharmaceutical, Cipla, Alkem Laboratories, Mankind Pharma, Lupin, Torrent Pharma, Zydus Lifesciences, Dr. Reddy's Laboratories, Ipca Laboratories, Abbott India, Pfizer India, Ajanta Pharma, Aurobindo Pharma, Natco Pharma, Biocon, Piramal Pharma, and Sanofi India.

Scope of India Pharmaceuticals Industry Strategic Research Report 2026-2031

• This report provides forecast data by value (USD Billion) for the India Pharmaceuticals Market (IPM), with 2025 as the base year and real historical data from 2022.
• This report provides segmentation by therapy type and by distribution channel/application.
• This report provides region-wise (West India, North India, South India, East India, Central India) and state-wise forecast data by value.
• This report identifies key growth drivers and inhibitors affecting the India Pharmaceuticals Market.
• This report provides company profiles including Company Overview, Financial Performance, Business Strategy, and SWOT Analysis for 17 officially-verified companies.
• This report provides Porter's Five Forces, PESTLE, and SWOT analysis for the India Pharmaceuticals Market.
• This report identifies key future trends including the GLP-1 biosimilar revolution and Ayushman Bharat-driven demand expansion.

Who can use the India Pharmaceuticals Industry Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the India Pharmaceuticals Market. Some of the intended users are:

• C-level executives and Company Directors in pharmaceutical and healthcare companies
• Investment managers, Financial professionals, and Venture Capitalists
• Portfolio Managers and Equity Research Analysts covering Indian pharmaceuticals
• Anyone operating in the India pharmaceutical value chain.